VENUS MEDTECH-B (02500) Submits CE MDR Certification Application for Cardiovalve Transcatheter Tricuspid Valve Replacement System

Stock News

2025/12/24

VENUS MEDTECH-B (02500) announced that the group has recently submitted the complete application for CE MDR certification of its Cardiovalve transcatheter tricuspid valve replacement system (Cardiovalve System) to the European Notified Body. The Cardiovalve System is a transcatheter intervention replacement product designed to treat both mitral regurgitation and tricuspid regurgitation. Compared to similar products, the Cardiovalve System's transfemoral venous approach significantly enhances treatment safety. Its large annulus design, with a maximum diameter of 55mm, is suitable for approximately 95% of the patient population. Additionally, the system's unique short-frame design effectively reduces the risk of ventricular outflow tract obstruction. The Cardiovalve System features a simple, safe, and highly reproducible operation, requiring only three steps: positioning, anchoring, and deployment.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1156767735"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156767735\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156767735?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 07:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156767735","market":"us","top_or_hot":-1,"title":"VENUS MEDTECH-B (02500) Submits CE MDR Certification Application for Cardiovalve Transcatheter Tricuspid Valve Replacement System","media":"Stock News","content":"<p>VENUS MEDTECH-B (02500) announced that the group has recently submitted the complete application for CE MDR certification of its Cardiovalve transcatheter tricuspid valve replacement system (Cardiovalve System) to the European Notified Body. The Cardiovalve System is a transcatheter intervention replacement product designed to treat both mitral regurgitation and tricuspid regurgitation. Compared to similar products, the Cardiovalve System's transfemoral venous approach significantly enhances treatment safety. Its large annulus design, with a maximum diameter of 55mm, is suitable for approximately 95% of the patient population. Additionally, the system's unique short-frame design effectively reduces the risk of ventricular outflow tract obstruction. The Cardiovalve System features a simple, safe, and highly reproducible operation, requiring only three steps: positioning, anchoring, and deployment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VENUS MEDTECH-B (02500) Submits CE MDR Certification Application for Cardiovalve Transcatheter Tricuspid Valve Replacement System</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVENUS MEDTECH-B (02500) Submits CE MDR Certification Application for Cardiovalve Transcatheter Tricuspid Valve Replacement System\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-12-24 07:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>VENUS MEDTECH-B (02500) announced that the group has recently submitted the complete application for CE MDR certification of its Cardiovalve transcatheter tricuspid valve replacement system (Cardiovalve System) to the European Notified Body. The Cardiovalve System is a transcatheter intervention replacement product designed to treat both mitral regurgitation and tricuspid regurgitation. Compared to similar products, the Cardiovalve System's transfemoral venous approach significantly enhances treatment safety. Its large annulus design, with a maximum diameter of 55mm, is suitable for approximately 95% of the patient population. Additionally, the system's unique short-frame design effectively reduces the risk of ventricular outflow tract obstruction. The Cardiovalve System features a simple, safe, and highly reproducible operation, requiring only three steps: positioning, anchoring, and deployment.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02500","symbol_name":"啓明醫療-B","start_time":0,"source_url":"","article_id":"1156767735","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156767735","pubTimestamp":1766531796,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VENUS MEDTECH-B (02500) announced that the group has recently submitted the complete application for CE MDR certification of its Cardiovalve transcatheter tricuspid valve replacement system...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02500":"启明医疗-B","BK1583":"高瓴概念","BK4585":"ETF&股票定投概念","CE":"塞拉尼斯","BK4109":"特种化学制品","BK1574":"生物医药B类股","BK1100":"医疗保健设备","BK4588":"碎股"},"translate_title":"启明医疗-B(02500)提交心瓣膜经导管三尖瓣置换系统CE MDR认证申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02500":1,"CE":1},"content_text":"VENUS MEDTECH-B (02500) announced that the group has recently submitted the complete application for CE MDR certification of its Cardiovalve transcatheter tricuspid valve replacement system (Cardiovalve System) to the European Notified Body. The Cardiovalve System is a transcatheter intervention replacement product designed to treat both mitral regurgitation and tricuspid regurgitation. Compared to similar products, the Cardiovalve System's transfemoral venous approach significantly enhances treatment safety. Its large annulus design, with a maximum diameter of 55mm, is suitable for approximately 95% of the patient population. Additionally, the system's unique short-frame design effectively reduces the risk of ventricular outflow tract obstruction. The Cardiovalve System features a simple, safe, and highly reproducible operation, requiring only three steps: positioning, anchoring, and deployment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}